These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1422085)

  • 1. Reversal of the malignant phenotype by an anti-ras ribozyme.
    Kashani-Sabet M; Funato T; Tone T; Jiao L; Wang W; Yoshida E; Kashfinn BI; Shitara T; Wu AM; Moreno JG
    Antisense Res Dev; 1992; 2(1):3-15. PubMed ID: 1422085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of EJ cells tumorigenicity.
    Tone T; Kashani-Sabet M; Funato T; Shitara T; Yoshida E; Kashfian BI; Horng M; Fodstadt O; Scanlon KJ
    In Vivo; 1993; 7(6A):471-6. PubMed ID: 8193263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of an anti-ras ribozyme to alter the malignant phenotype of a human bladder cancer cell line.
    Eastham JA; Ahlering TE
    J Urol; 1996 Sep; 156(3):1186-8. PubMed ID: 8709343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancer.
    Irie A; Anderegg B; Kashani-Sabet M; Ohkawa T; Suzuki T; Halks-Miller M; Curiel DT; Scanlon KJ
    Antisense Nucleic Acid Drug Dev; 1999 Aug; 9(4):341-9. PubMed ID: 10463078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribozymes designed to inhibit transformation of NIH3T3 cells by the activated c-Ha-ras gene.
    Koizumi M; Kamiya H; Ohtsuka E
    Gene; 1992 Aug; 117(2):179-84. PubMed ID: 1639266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoplastic progression by EJ/ras at different steps of transformation in vitro of human uroepithelial cells.
    Pratt CI; Kao CH; Wu SQ; Gilchrist KW; Oyasu R; Reznikoff CA
    Cancer Res; 1992 Feb; 52(3):688-95. PubMed ID: 1310069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribozyme against mutant K-ras mRNA suppresses tumor growth of pancreatic cancer.
    Kijima H; Yamazaki H; Nakamura M; Scanlon KJ; Osamura RY; Ueyama Y
    Int J Oncol; 2004 Mar; 24(3):559-64. PubMed ID: 14767540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of H-ras-mediated transformation in NIH3T3 cells by a ras ribozyme.
    Funato T; Shitara T; Tone T; Jiao L; Kashani-Sabet M; Scanlon KJ
    Biochem Pharmacol; 1994 Oct; 48(7):1471-5. PubMed ID: 7945447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromosome losses in tumorigenic revertants of EJ/ras-expressing somatic cell hybrids.
    Pratt CI; Wu SQ; Bhattacharya M; Kao C; Gilchrist KW; Reznikoff CA
    Cancer Genet Cytogenet; 1992 Apr; 59(2):180-90. PubMed ID: 1316224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme.
    Kashani-Sabet M; Funato T; Florenes VA; Fodstad O; Scanlon KJ
    Cancer Res; 1994 Feb; 54(4):900-2. PubMed ID: 8313379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme.
    Feng M; Cabrera G; Deshane J; Scanlon KJ; Curiel DT
    Cancer Res; 1995 May; 55(10):2024-8. PubMed ID: 7743496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A ribozyme specifically suppresses transformation and tumorigenicity of Ha-ras-oncogene-transformed NIH/3T3 cell lines.
    Chang MY; Won SJ; Liu HS
    J Cancer Res Clin Oncol; 1997; 123(2):91-9. PubMed ID: 9030247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense-fos RNA causes partial reversion of the transformed phenotypes induced by the c-Ha-ras oncogene.
    Ledwith BJ; Manam S; Kraynak AR; Nichols WW; Bradley MO
    Mol Cell Biol; 1990 Apr; 10(4):1545-55. PubMed ID: 1690847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribozyme as an approach for growth suppression of human pancreatic cancer.
    Kijima H; Scanlon KJ
    Mol Biotechnol; 2000 Jan; 14(1):59-72. PubMed ID: 10911615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of c-Ha-ras gene expression by hammerhead ribozymes containing a stable C(UUCG)G hairpin loop.
    Koizumi M; Kamiya H; Ohtsuka E
    Biol Pharm Bull; 1993 Sep; 16(9):879-83. PubMed ID: 8268855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ribozyme targeted the point-mutation of activated oncogene inhibits its expression in vivo].
    Liu G; Chen Y; Zhao X; Dong Y; Chen D
    Yi Chuan Xue Bao; 1996; 23(6):477-85. PubMed ID: 9084224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma.
    Theodorescu D; Cornil I; Fernandez BJ; Kerbel RS
    Proc Natl Acad Sci U S A; 1990 Nov; 87(22):9047-51. PubMed ID: 2247480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice.
    Gray GD; Hernandez OM; Hebel D; Root M; Pow-Sang JM; Wickstrom E
    Cancer Res; 1993 Feb; 53(3):577-80. PubMed ID: 8425190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of a ribozyme-adenoviral vector against K-ras mutant human lung cancer cells.
    Zhang YA; Nemunaitis J; Tong AW
    Mol Biotechnol; 2000 May; 15(1):39-49. PubMed ID: 10911621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of tumorigenicity with continued expression of the c-Ha-ras oncogene in EJ bladder carcinoma-human fibroblast hybrid cells.
    Geiser AG; Der CJ; Marshall CJ; Stanbridge EJ
    Proc Natl Acad Sci U S A; 1986 Jul; 83(14):5209-13. PubMed ID: 3523486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.